FDA Approves HER2 Test for Breast Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration said today it has approved a genetic test to help healthcare professionals determine whether breast cancer patients are candidates for Herceptin (trastuzumab).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.